News
Media
Conferences
Publications
CME/CE
Resources
Subscribe
About
Partnerships

Opinion|Videos|December 3, 2024

Addressing Challenges in Accessing Traditional STI Screening Options

Author(s)Kameelah Phillips, MD, FACOG, NCMP

The panelist discusses how asymptomatic sexually transmitted infections (STIs) can silently impact overall health, emphasizing the importance of comprehensive screening and education, particularly for less known STIs like trichomoniasis and Mycoplasma genitalium, while exploring how newer testing methods like nucleic acid amplification testing (NAAT) can address challenges in traditional screening access and improve patient care.

Episodes in this series

Kameelah Phillips, MD, FACOG, NCMP, is featured in this series.

EP. 1 Importance of STI Screening to Detect Uncommon Infections

Kameelah Phillips, MD, FACOG, NCMP, is featured in this series.

EP. 2 Addressing Challenges in Accessing Traditional STI Screening Options

Kameelah Phillips, MD, FACOG, NCMP, is featured in this series.

EP. 3 Recommended Guidelines for Cervical Cancer Screening

Kameelah Phillips, MD, FACOG, NCMP, is featured in this series.

EP. 4 HPV Self-Collection Screening: What OB/GYNs Should Know

Kameelah Phillips, MD, FACOG, NCMP, is featured in this series.

EP. 5 Building Physician-Patient Trust to Increase Timely Screening Rates

Video content above is prompted by the following:

In what ways can asymptomatic STIs impact overall health, and why is screening important?
- How can health care providers effectively raise awareness about less commonly known STIs like trichomoniasis and Mycoplasma genitalium?
What challenges do patients face when accessing traditional STI screenings testing, and how can these be addressed?
- How does the use of newer screening methods like NAAT impact patient access to necessary screenings?

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Latest CME

‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis

‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis

Raj Chovatiya, MD, PhD, MSCI, FAAD; Michael Rubio, PA-C, MMSc

Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances

Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances

Kathleen N. Moore, MD, MS, FASCO; Susana Banerjee, MBBS, MA, FRCP, PhD; David M. O’Malley, MD; Ritu Salani, MD, MBA

Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer

Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS, FASCO; David M. O’Malley, MD

Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care

Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care

Kathleen N. Moore, MD, MS, FASCO; Ritu Salani, MD, MBA

Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials

Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials

Kathleen N. Moore, MD, MS, FASCO; Prof Susana Banerjee, MBBS, MA, FRCP, PhD

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations

John Brandsema, MD; Neelam Goyal, MD

Expert Illustrations and Commentaries™: Visualizing Glucocorticoid Receptor Modulation in Platinum-Resistant Ovarian Cancer—Looking at Novel Pathways With an Eye Toward the Future of Treatment

Expert Illustrations and Commentaries™: Visualizing Glucocorticoid Receptor Modulation in Platinum-Resistant Ovarian Cancer—Looking at Novel Pathways With an Eye Toward the Future of Treatment

Rachel N. Grisham, MD; Domenica Lorusso, MD, PhD

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients With Platinum-Resistant Ovarian Cancer

Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients With Platinum-Resistant Ovarian Cancer

Ritu Salani, MD, MBA; Jill Alldredge, MD; Emely Alfaro, MS, RN, CNS, OCN

Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients with Platinum-Resistant Ovarian Cancer

Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients with Platinum-Resistant Ovarian Cancer

Ritu Salani, MD, MBA; Emely Alfaro, MS, RN, CNS, OCN; Jill Alldredge, MD

Addressing Healthcare Inequities: Detecting and Managing the Uncommon – Hemophilia in Women

Addressing Healthcare Inequities: Detecting and Managing the Uncommon – Hemophilia in Women

Danielle Nance, MD; Kimberley Youkhana, MD

Trending on Contemporary OB/GYN

Boosting cervical cancer screening in FQHCs could reach 1.8 million more women

Researchers identify 4 distinct PCOS subtypes to guide treatment

FDA grants IDE approval for FemBloc non-surgical permanent birth control

FDA approves fosfomycin for treating cUTIs

Elective egg freezing on the rise, but few patients return to use preserved oocytes

© 2025 MJH Life Sciences^®

All rights reserved.